This is the NIH web page on the C-TAP licenses.
techtransfer.nih.gov/policy/ctap

@who MedicinesPatentPool

#sccr42 Jukka if the signal disappears immediately, how does it also last 20 years?

Moderna’s filing is an important reminder of existing flexibilities the U.S.G. can leverage to expand vaccine access. At least when doing so is consistent with a company’s legal or financial interests, they are willing to embrace such flexibility. keionline.org/37751

'You could simply hold a hearing on a petition regarding the price of Xtandi, a prostate cancer drug that costs $190,000 for a single year of treatment for prostate cancer, six times what Japanese patients pay.' youtube.com/watch?v=tMMB3d…

New from James Packard Love: The Proposed TRIPS Compromise Risks Setting Several Bad Precedents blog.petrieflom.law.harvard.edu/2022/04/07/tri…

I think they will continue to do business with the largest public sector funder of R&D, especially because there can be predictability. In the private sector, we don't expect businesses to engage only in one-sided transactions. Ironically, these arguments are not innovative.

Liza Vertinsky in Health Affairs:

Exercising March-In Rights Would Make Biomedical Public-Private Partnerships Stronger

disq.us/t/46k84rh

'Practically and legally, making drugs available to the public on reasonable terms surely must mean making them available at a reasonable price.'

commondreams.org/views/2022/03/… via Kathryn Ardizzone KEI Peter Arno

#MakeMedsAffordable

It's not personal; it's political. It impacts the public. Who among us hasn't felt or known someone who felt the pain of excessive drug prices? Two men cannot enact laws in the US, so it's time to stop making Bayh and Dole the judge of march-in rights. commondreams.org/views/2022/03/…

Comment by Kathryn Ardizzone KEI in response to Astellas op-ed in STAT discusses the significant of statements by former members of Congress, working as lobbyists, to establish legislative intent.

statnews.com/2022/03/03/ina…

The @HHS announcement today about the World Health Organization (WHO) C-TAP comes after a long period of the major donors ignoring it, in part because of opposition from Gates and pharma.

Clare Love, Robert Sachs and Eric Sawyer respond to Astellas Feb 9 Statement on Xtandi Bayh Dole march in and government use case

keionline.org/37446

Democrats urge HHS to 'march-in' or enable 'government-use' rights to make Xtandi less expensive endpts.com/democrats-urge… Kathryn Ardizzone KEI James Packard Love

“I’m … concerned because you’ve got a full court press on [this] now. This is all over the place…There’s a huge effort now to influence the Biden administration politically,” said Joe Allen, executive director of the Bayh-Dole Coalition.

It's an exceedingly strong case, yes.

Prostate cancer drug Xtandi costs as much as six times more in the U.S. than it does overseas, despite being developed by U.S. taxpayer dollars.

I'm urging HHS.gov to use its authority to dramatically lower this drug's price for Americans and stop Big Pharma's price-gouging.

KEI's take on the MPP-Merck Molnupiravir license, with a break down of the controversial termination for challenge clause. keionline.org/36859

USG's $1.2 billion contract for Merck COVID-19 drug molnupiravir, obtained through FOIA. Why are they selectively withholding intellectual property terms? keionline.org/36698

Roundtable on March-in for Patents on Federally-funded Inventions, October 6, 2021 from 2pm to 4pm
keionline.org/36565